SMARCC2 and neoplasm: We observed in our study that the PI3K–AKT pathway was significantly inhibited when SMARCC2 was overexpressed; however, the PI3K–AKT promoter SC79 only partially reversed these tumor suppressor effects, suggesting that other epigenetic factors may be involved.